103 related articles for article (PubMed ID: 28627792)
1. β-Catenin in desmoid-type fibromatosis: deep insights into the role of T41A and S45F mutations on protein structure and gene expression.
Colombo C; Belfiore A; Paielli N; De Cecco L; Canevari S; Laurini E; Fermeglia M; Pricl S; Verderio P; Bottelli S; Fiore M; Stacchiotti S; Palassini E; Gronchi A; Pilotti S; Perrone F
Mol Oncol; 2017 Nov; 11(11):1495-1507. PubMed ID: 28627792
[TBL] [Abstract][Full Text] [Related]
2. Utility of LEF1 to differentiate desmoid fibromatosis from its histologic mimics.
Jobbagy S; Lozano-Calderon S; Mullen JT; Nielsen GP; Hung YP; Chebib I
Virchows Arch; 2024 May; 484(5):807-813. PubMed ID: 38503969
[TBL] [Abstract][Full Text] [Related]
3. Desmoid Fibromatosis With TP53 Mutation and Striking Nuclear Pleomorphism.
Foster CR; Strauss M; Hornick JL; Habeeb O
Int J Surg Pathol; 2023 Dec; 31(8):1565-1571. PubMed ID: 36908221
[TBL] [Abstract][Full Text] [Related]
4. CTNNB1 mutation-driven hybrid tumor: desmoid fibromatosis with an unusual associated epithelioid component arising in association with a neuromuscular choristoma.
Zheng X; He X; Lu Y; Chen C; Zhang H
Virchows Arch; 2024 Apr; 484(4):715-720. PubMed ID: 38183458
[TBL] [Abstract][Full Text] [Related]
5. Desmoid-type fibromatosis of the mesentery: a clinicopatho-logical and genetic analysis of 9 cases.
Wang Q; Zhang L; Weng S; Zhou J; Gan M
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2023 Jun; 52(3):379-385. PubMed ID: 37476949
[TBL] [Abstract][Full Text] [Related]
6. PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis.
Hu J; Hameed MR; Agaram NP; Whiting KA; Qin LX; Villano AM; O'Connor RB; Rozenberg JM; Cohen S; Prendergast K; Kryeziu S; White RL; Posner MC; Socci ND; Gounder MM; Singer S; Crago AM
Clin Cancer Res; 2024 Jan; 30(2):450-461. PubMed ID: 37943631
[TBL] [Abstract][Full Text] [Related]
7. Preclinical efficacy of the Wnt/β-catenin pathway inhibitor BC2059 for the treatment of desmoid tumors.
Braggio DA; Costas C de Faria F; Koller D; Jin F; Zewdu A; Lopez G; Batte K; Casadei L; Welliver M; Horrigan SK; Han R; Larson JL; Strohecker AM; Pollock RE
PLoS One; 2022; 17(10):e0276047. PubMed ID: 36240209
[TBL] [Abstract][Full Text] [Related]
8. Sporadic desmoid-type fibromatosis: a stepwise approach to a non-metastasising neoplasm--a position paper from the Italian and the French Sarcoma Group.
Gronchi A; Colombo C; Le Péchoux C; Dei Tos AP; Le Cesne A; Marrari A; Penel N; Grignani G; Blay JY; Casali PG; Stoeckle E; Gherlinzoni F; Meeus P; Mussi C; Gouin F; Duffaud F; Fiore M; Bonvalot S;
Ann Oncol; 2014 Mar; 25(3):578-583. PubMed ID: 24325833
[TBL] [Abstract][Full Text] [Related]
9. TGF-β signaling promotes desmoid tumor formation via CSRP2 upregulation.
Li Y; Fujishita T; Mishiro-Sato E; Kojima Y; Niu Y; Taketo MM; Urano Y; Sakai T; Enomoto A; Nishida Y; Aoki M
Cancer Sci; 2024 Feb; 115(2):401-411. PubMed ID: 38041233
[TBL] [Abstract][Full Text] [Related]
10. Desmoid Tumors and Celecoxib with Sorafenib.
Benech N; Walter T; Saurin JC
N Engl J Med; 2017 Jun; 376(26):2595-2597. PubMed ID: 28657872
[No Abstract] [Full Text] [Related]
11. Is immunohistochemical staining for β-catenin the definitive pathological diagnostic tool for desmoid-type fibromatosis? A multi-institutional study.
Koike H; Nishida Y; Kohno K; Shimoyama Y; Motoi T; Hamada S; Kawai A; Ogose A; Ozaki T; Kunisada T; Matsumoto Y; Matsunobu T; Ae K; Gokita T; Sakai T; Shimizu K; Ishiguro N
Hum Pathol; 2019 Feb; 84():155-163. PubMed ID: 30292627
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological assessment of PD-1/PD-L1 immune checkpoint expression in desmoid tumors.
Hashimoto K; Nishimura S; Shinyashiki Y; Ito T; Kakinoki R; Akagi M
Eur J Histochem; 2023 Apr; 67(2):. PubMed ID: 37098880
[TBL] [Abstract][Full Text] [Related]
13. Biclonal Desmoid-Type Fibromatosis With Two Beta-Catenin Mutations: Evidence for the Recruitment of Normal Myofibroblasts.
Skubitz KM; Murugan P; Corless CL
Cureus; 2022 Aug; 14(8):e28006. PubMed ID: 36134040
[TBL] [Abstract][Full Text] [Related]
14. Intraabdominal sporadic desmoid tumors and inflammation: an updated literature review and presentation and insights on pathogenesis of synchronous sporadic mesenteric desmoid tumors occurring after surgery for necrotizing pancreatitis.
Prete F; Rotelli M; Stella A; Calculli G; Sgaramella LI; Amati A; Resta N; Testini M; Gurrado A
Clin Exp Med; 2023 Jul; 23(3):607-617. PubMed ID: 35913675
[TBL] [Abstract][Full Text] [Related]
15. Molecular rationale for SARS-CoV-2 spike circulating mutations able to escape bamlanivimab and etesevimab monoclonal antibodies.
Laurini E; Marson D; Aulic S; Fermeglia A; Pricl S
Sci Rep; 2021 Oct; 11(1):20274. PubMed ID: 34642465
[TBL] [Abstract][Full Text] [Related]
16. Clinicopathological features of 70 desmoid-type fibromatoses confirmed by β-catenin immunohistochemical staining and CTNNB1 mutation analysis.
An J; Woo HY; Lee Y; Kim HS; Jeong J; Kim SK
PLoS One; 2021; 16(4):e0250619. PubMed ID: 33914771
[TBL] [Abstract][Full Text] [Related]
17. Development, Validation, and Visualization of A Web-Based Nomogram for Predicting the Recurrence-Free Survival Rate of Patients With Desmoid Tumors.
Liu H; Huang K; Li T; Yang T; Liao Z; Zhang C; Xiang L; Chen Y; Yang J
Front Oncol; 2021; 11():634648. PubMed ID: 33718222
[TBL] [Abstract][Full Text] [Related]
18. The majority of β-catenin mutations in colorectal cancer is homozygous.
Arnold A; Tronser M; Sers C; Ahadova A; Endris V; Mamlouk S; Horst D; Möbs M; Bischoff P; Kloor M; Bläker H
BMC Cancer; 2020 Oct; 20(1):1038. PubMed ID: 33115416
[TBL] [Abstract][Full Text] [Related]
19. Computational Alanine Scanning and Structural Analysis of the SARS-CoV-2 Spike Protein/Angiotensin-Converting Enzyme 2 Complex.
Laurini E; Marson D; Aulic S; Fermeglia M; Pricl S
ACS Nano; 2020 Sep; 14(9):11821-11830. PubMed ID: 32833435
[TBL] [Abstract][Full Text] [Related]
20. Clinical benefit of methotrexate plus vinorelbine chemotherapy for desmoid fibromatosis (DF) and correlation of treatment response with MRI.
Ingley KM; Burtenshaw SM; Theobalds NC; White LM; Blackstein ME; Gladdy RA; Thipphavong S; Gupta AA
Cancer Med; 2019 Sep; 8(11):5047-5057. PubMed ID: 31301110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
